Clinical Trial Update: Blinatumomab for Treatment of Refractory Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

This item reports a Phase 2/Phase 3 clinical trial evaluating blinatumomab for refractory myasthenia gravis, which is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Da, Yuwei, M.D. | Conditions: Myasthenia Gravis | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING